Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus

Plain-language guide to PMID 20189610 (2010): randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin in 6 patients.

Key Facts

PMID: 20189610
Journal: Metabolism: clinical and experimental
Year: 2010
Study type: Randomized Controlled Trial
Authors: de Sá LB et al. (7 authors)
DOI: 10.1016/j.metabol.2010.01.021

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin.

Ghrelin's effects in patients with T1DM have not been evaluated.

The GH-releasing hormone (GHRH)-induced GH release was also evaluated.

Who Took Part

According to the abstract, 6 patients were involved.

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

Ghrelin's effects in patients with T1DM have not been evaluated.

The GH-releasing hormone (GHRH)-induced GH release was also evaluated.

Topics PubMed links to this paper include Adrenocorticotropic Hormone, Diabetes Mellitus, Type 1, Ghrelin, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hydrocortisone and Oligopeptides.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Ghrelin in 6 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Ghrelin compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.